THE JOURNAL OF
CLINICAL PSYCHIATRY
THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Cross-Cutting Symptom Domains Predict Functioning in Psychotic Disorders

Author(s): Julia M. Longenecker, PhD; R. Michael Bagby, PhD; Kwame McKenzie, PhD; Bruce G. Pollock, MD, PhD; Tony P. George, MD; Peter Voore, MD; and Lena C. Quilty, PhD

DOI Number: 10.4088/JCP.20m13288

List of Supplementary Material for the article

1. Table 1 — Association of Negative and Cross-Cutting Symptoms with Functioning
2. Table 2 — Concurrent Association Between Level 1 Cross-Cutting Measures and Functioning Domains
3. Table 3 — Cross-Cutting Symptoms Prospectively Predict Change in Functioning

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1.

Association of Negative & Cross-Cutting Symptoms with Functioning[a]

	β	Std. Error	95% CI	p-value	
Model 1					
Intercept	*1.26*	*0.20*	*[0.86, 1.65]*		
Age	0.10	0.06	[-0.02, 0.22]	0.091	
Gender	-0.17	0.12	[-0.4, 0.06]	0.154	
Psychosis	0.19	0.06	[0.07, 0.31]	0.003	*
Negative Sx	0.11	0.06	[-0.02, 0.23]	0.094	
Model 2					
Intercept	*1.08*	*0.15*	*[0.79, 1.36]*		
Age	0.11	0.06	[0, 0.22]	0.050	†
Gender	-0.08	0.09	[-0.26, 0.1]	0.395	
Internalizing	0.31	0.05	[0.21, 0.41]	0.000	*
Substance Use	0.09	0.04	[0, 0.17]	0.049	*
Psychosis	0.05	0.05	[-0.05, 0.14]	0.314	
Negative Sx	0.05	0.05	[-0.04, 0.15]	0.275	
Psy x Int	0.07	0.04	[-0.01, 0.16]	0.103	
Psy x Sub	-0.03	0.04	[-0.11, 0.06]	0.510	
Sub x Int	0.09	0.04	[0.01, 0.16]	0.021	*

[a]Symptom domains are Level 1 Cross-Cutting Measures at Time 1. Predicted functioning levels are WHO-DAS-II self-ratings at Time 1. Model 1, R^2 =.17; Model 2, R^2 =.44.
† The result is marginally significant: $0.05 \geq p \leq 0.08$; *$p<0.05$; **$p<0.001$
Abbreviations. Int = internalizing; Psy = Psychosis; Sub = Substance Use.

Supplementary Table 2.

Concurrent Association Between Level 1 Cross-cutting Measures and Functioning Domains[a]

	WHO-DAS II Subscales					
	Communication	Mobility	Self-Care	Interpersonal	Life Activities	Participation in Society
Model 1						
Intercept	*1.19(.20)*	*.94(.21)*	*.76(.23)*	*1.28(.26)*	*1.42(.33)*	*1.33(.24)*
Age	.08(.06), p=.22	**.16(.07), p=.01**	.07(.07), p=.34	.03(.06), p=.70	.14(.08), p=.10	.07(.07), p=.35
Gender	-.17(.12), p=.15	-.14(.13), p=.26	-.15(.13), p=.27	-.12(.15), p=.42	-.22(.18), p=.24	-.04(.14), p=.80
Psy	**.23(.06), p<.001**	**.15(.07), p=.02**	.13(.07), p=.05	**.23(.07), p<.001**	**.21(.09), p=.03**	**.32(.07), p<.001**
Model 2						
Intercept	*1.59(.26)*	*1.16(.27), p<.001*	*.85(.27)*	*1.35(.27)*	*1.32(.27)*	*1.52(.26)*
Age	.10(.06), p=.11	**.17(.07), p=.01**	.08(.07), p=.24	.05(.06), p=.41	.15(.08), p=.07	.09(.07), p=.18
Gender	-.11(.1), p=.25	-.10(.12), p=.39	-.10(.11), p=.37	-.06(.13), p=.64	-.15(.16), p=.35	.02(.12), p=.85
Int	**.33(.05), p<.001**	**.17(.06), p=.01**	**.23(.07), p<.001**	**.29(.07), p<.001**	**.37(.09), p<.001**	**.39(.07), p<.001**
Sub	.04(.05), p=.38	.05(.06), p=.48	**.12(.05), p=.02**	**.18(.07), p=.01**	.15(.08), p=.07	.04(.06), p=.43
Psy	.08(.06), p=.16	.07(.07), p=.28	-.02(.06), p=.79	.06(.07), p=.36	.02(.08), p=.84	**.14(.07), p=.04**
Psy x Int	.03(.05), p=.51	.04(.06), p=.46	.10(.06), p=.13	.03(.06), p=.59	.03(.08), p=.69	.05(.05), p=.4
Psy x Sub	-.06(.06), p=.29	-.06(.06), p=.25	.05(.06), p=.35	.04(.06), p=.54	-.05(.09), p=.57	-.05(.07), p=.49
Sub x Int	.08(.04), p=.05	**.11(.05), p=.02**	.05(.05), p=.34	**.13(.05), p=.02**	.06(.08), p=.43	.08(.05), p=.16
R^2						
Model 1	0.14	0.10	0.05	0.08	0.08	0.17
Model 2	0.39	0.21	0.22	0.30	0.25	0.42

[a]Symptom domains at Time 1 and WHO-DAS-II client-rated disability measure subscales at Time 1 are included in the models. Values listed before parentheses are standardized (β) estimates of each indicator; standard error is in parentheses. Boldface text indicates significant values ($p<.05$).
Abbreviations: Int = Internalizing; Psy = Psychosis; Sub = Substance Use.

Supplementary Table 3.

Cross-Cutting Symptoms Prospectively Predict Change in Functioning[a]

	β	Std. Error	95% CI	p-value	
Model 1					
Intercept	*.11*	*.20*	*[-.29, .50]*		
Age	.09	.05	[-.01, .19]	.076	†
Gender	.00	.09	[-.17, .16]	.979	
Days Between Visits	.00	.00	[-.01, .01]	.623	
WHO-DAS-II Baseline	.68	.09	[.50, .86]	< .001	*
Psychosis	.05	.05	[-.04, .14]	.261	
Model 2					
Intercept	*.15*	*.20*	*[-.24, .55]*		
Age	.10	.05	[.00, .19]	.053	†
Gender	-.01	.08	[-.17, .16]	.953	
Days Between Visits	.00	.00	[-.01, .01]	.481	
WHO-DAS-II Baseline	.64	.10	[.44, .84]	< .001	*
Internalizing	.11	.06	[-.01, .23]	.069	†
Substance Use	-.03	.04	[-.10, .05]	.501	
Psychosis	.03	.04	[-.05, .12]	.449	
Psy x Int	-.05	.06	[-.16, .06]	.361	
Psy x Sub	.00	.04	[-.08, .08]	.985	
Sub x Int	-.02	.04	[-.10, .07]	.679	

[a] Symptom domains are Level 1 Cross-Cutting Measures at Time 1. Predicted real-world functioning is WHO-DAS-II self-ratings at Time 3. After correction for baseline functioning levels (WHO-DAS-II at Time 1), the effect of internalizing was at the threshold of significance. Model 1, R^2 =.57; Model 2, R^2 =.60.

† The result is marginally significant: $0.05 \geq p \leq 0.08$; *p<0.05; **p<0.001

Abbreviations. Int = Internalizing; Psy = Psychosis; *Sub* = Substance Use.